Funding profile · Digital health, migraine genomics

Mable

A single SEC filing and one announced seed round make up Mable’s public financing record. The UK operating entity was struck off in 2023, and no filing or report names a buyer, despite the company sometimes being labeled acquired.

$3.2MSeed round, company-reported (Jul 2022)
$3.08MSold per Form D, filed Dec 2021
11Investors in the Form D round
0Acquisitions or exit filings found in the public record

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2021 (year not stated on company page) Y Combinator Not disclosed Y Combinator Company page
Dec 14, 2021 Seed, first sale under Form D $3,081,917 sold; total offering not stated 11 investors, including Parul Singh of Initialized Capital Form D
Jul 27, 2022 Seed, announced $3.2M Led by Initialized Capital; First In Ventures, Arkitekt Ventures, Inaki Berenguer Axios
Aug 8, 2023 Wind-down, not a financing Not applicable Neurolytic Healthcare Ltd struck off the UK register Companies House

What the filings show

Neurolytic Healthcare, Inc. · Form D · filed Dec 29, 2021

First sale
Dec 14, 2021
Offered
Indefinite, amount not stated
Sold
$3,081,917
Investors
11 · average about $280,175
Exemption
Rule 506(b)
Related persons
Roman Rothaermel (CEO, director, promoter); Inna Thalmann; Tom Kent; Parul Singh (director)
Filing
SEC EDGAR, CIK 0001901484

Reading the filings

  1. The filed amount tracks the announced amount, closely.Eleven investors had put in $3,081,917 by the Form D’s December 29, 2021 filing date. When Axios reported the round publicly seven months later, in July 2022, it put the size at $3.2 million. The gap, about $118,000, is small enough to be a late close that never triggered an amended Form D, though EDGAR shows no such amendment.
  2. The checks are institutional size.Eleven investors averaging about $280,175 each is consistent with a round led by an institutional seed fund, Initialized Capital, rather than a wide angel syndicate.
  3. The board was small and stayed small.The filing names four related persons: founders Roman Rothaermel and Inna Thalmann, Chief Technology Officer Tom Kent, and Parul Singh, a director tied to lead investor Initialized Capital. No later filing adds or removes anyone.
  4. Only one Form D was ever filed.No amendment and no second offering appear under Neurolytic Healthcare’s CIK. If a Series A or bridge round followed the 2022 seed, it left no Regulation D notice on EDGAR.
  5. The 2023 paperwork reads like a shutdown, not a sale.A secured charge registered against Neurolytic Healthcare Ltd in February 2022 was marked satisfied on May 5, 2023. Five days later the company applied to strike itself off the UK register, a route companies use to dissolve voluntarily, and the strike off became final on August 8, 2023. An acquisition normally leaves a share transfer and a continuing legal entity behind it, not a strike off application.
  6. No public record names an acquirer.PitchBook marks Neurolytic Healthcare’s status as Out of Business, effective the same August 8, 2023 date as the Companies House strike off, not as acquired. No SEC filing, press release, or news report identifies a buyer for Mable’s technology, patient base, or team. Anyone describing Mable as acquired is going beyond what the public record shows.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k) or PMA record found. The DNA test was described by the company as a CLIA-regulated Laboratory Developed Test, not FDA cleared. Not found
Reach Company said in Jul 2022 it was live in 10 states with a 5,000-person waitlist, planning to reach 42 states by end of Aug 2022. Company-stated
Clinical evidence No registered trial and no published study of the product found; company cited pharmacogenetic research from other conditions instead. Not found
UK entity status Neurolytic Healthcare Ltd, company number 11946343, dissolved via voluntary strike-off on Aug 8, 2023. Companies House
Website trymable.com now hosts unrelated marketing content from a UK hair-transplant clinic, checked Sep 2026. Independent

What to watch

  • Any SEC amendment to the 2021 Form D that would resolve the $118,000 gap between the filed and announced totals.
  • A public record naming an acquirer, if one exists; none was found in SEC, Companies House, or press records searched for this profile.
  • Whether the founders’ current roles, which public profiles place in venture capital, ever reference a sale of Mable’s assets.
  • Reuse of the trymable.com domain or the Mable brand by an unrelated party, which has already begun.

The Mable story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Bristle Health: Shared investor: Initialized. A saliva test that sequences the whole oral microbiome and sells the answer to consumers and to dental practices
  • Data Driven Bioscience: Shared investor: Initialized. A Durham company that sells hospital laboratories a kit for reading a tumor’s DNA and RNA in a single preparation, on the sequencer the lab already owns
  • Bodyport: Shared investor: Initialized. A bathroom scale that reads hemodynamic signals through bare feet
  • Truepill: Shared investor: Initialized. The pharmacy behind a generation of direct to consumer health brands

Sources

  1. Public recordForm D, Neurolytic Healthcare, Inc., CIK 0001901484SEC EDGAR · filed Dec 29, 2021
  2. Public recordNEUROLYTIC HEALTHCARE LTD company overview, company number 11946343Companies House · accessed Sep 2026
  3. Public recordNEUROLYTIC HEALTHCARE LTD filing historyCompanies House · accessed Sep 2026
  4. IndependentMable raises $3M for DNA-based migraine treatmentAxios, Erin Brodwin · Jul 27, 2022
  5. IndependentEarly Money: Here’s how this San Francisco startup aims to help migraine sufferersSilicon Valley Business Journal, Sonya Herrera · Aug 2, 2022
  6. IndependentNeurolytic Healthcare company profile, status Out of BusinessPitchBook · accessed Sep 2026
  7. IndependentNeurolytic Healthcare company and funding profileTracxn · accessed Sep 2026
  8. InterviewMigraines cost U.S. employers $13B a Year. Here’s How Mable Health is Helping to Personalize Migraine TreatmentsView from Initialized (Initialized Capital blog), Parul Singh · Jul 27, 2022
  9. CompanyWe’re Mable, the first company to individualize migraine care by using DNA (Reddit AMA)Reddit r/IAmA, u/mable_health · May 25, 2022
  10. CompanyMable: First personalized migraine clinic using genetics and telehealthY Combinator company page · accessed Sep 2026

Compiled from SEC, Companies House and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Mable. This page is not an offer to sell or a recommendation to buy any security.